Comparison of the activation of somatostatin- and neuropeptide Y-containing neuronal populations of the rat amygdala following two different anxiogenic stressors

Experimental Neurology

Volumn 238, Issue 1, 2012, Pages 52-63

  Butler, Ryan K ^a   White, L Casey ^a   Frederick Duus, Dani ^a   Kaigler, Kris F ^a   Fadel, Jim R ^a   Wilson, Marlene A ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Amygdala; Anxiety; C Fos; Elevated plus maze; Ferret; Neuropeptide Y; Somatostatin

Indexed keywords

BUTYRIC ACID; NEUROPEPTIDE Y; PROTEIN C FOS; SOMATOSTATIN;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASOLATERAL AMYGDALA; BRAIN NERVE CELL; BRAIN TISSUE; CELL ACTIVATION; CELL COUNT; CELL DIFFERENTIATION; CELL POPULATION; CENTRAL NUCLEUS (AMYGDALA); CONTROLLED STUDY; FERRET; HORMONE ACTION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MAZE TEST; MEDIAL AMYGDALA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; STRESS;

AMYGDALA; ANIMALS; ANXIETY; CEREBROVASCULAR CIRCULATION; DATA INTERPRETATION, STATISTICAL; FERRETS; IMMUNOHISTOCHEMISTRY; LIMBIC SYSTEM; MALE; NEURONS; NEUROPEPTIDE Y; ODORS; PREDATORY BEHAVIOR; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, LONG-EVANS; SOMATOSTATIN; STRESS, PSYCHOLOGICAL;

EID: 84866562034     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.08.002     Document Type: Article

References (54)

1. Baisley S.K., Cloninger C.L., Bakshi V.P. Fos expression following regimens of predator stress versus footshock that differentially affect prepulse inhibition in rats. Physiol. Behav. 2011, 104:796-803.
2. Blanchard D.C., Blanchard R.J. Innate and conditioned reactions to threat in rats with amygdaloid lesions. J. Comp. Physiol. Psychol. 1972, 81:281-290.
3. Blanchard D.C., Canteras N.S., Markham C.M., Pentkowski N.S., Blanchard R.J. Lesions of structures showing FOS expression to cat presentation: effects on responsivity to a Cat, Cat odor, and nonpredator threat. Neurosci. Biobehav. Rev. 2005, 29:1243-1253.
4. Buchan A.M., Sikora L.K., Levy J.G., McIntosh C.H., Dyck I., Brown J.C. An immunocytochemical investigation with monoclonal antibodies to somatostatin. Histochemistry 1985, 83:175-180.
5. Burghardt P.R., Wilson M.A. Microinjection of naltrexone into the central, but not the basolateral, amygdala blocks the anxiolytic effects of diazepam in the plus maze. Neuropsychopharmacology 2006, 31:1227-1240.
6. Butler R.K., Sharko A.C., Oliver E.M., Brito-Vargas P., Kaigler K.F., Fadel J.R., Wilson M.A. Activation of phenotypically-distinct neuronal subpopulations of the rat amygdala following exposure to predator odor. Neuroscience 2011, 175:133-144.
7. Carobrez A.P., Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20years on. Neurosci. Biobehav. Rev. 2005, 29:1193-1205.
8. Cassell M.D., Gray T.S., Kiss J.Z. Neuronal architecture in the rat central nucleus of the amygdala: a cytological, hodological, and immunocytochemical study. J. Comp. Neurol. 1986, 246:478-499.
9. Cassell M.D., Freedman L.J., Shi C. The intrinsic organization of the central extended amygdala. Ann. N. Y. Acad. Sci. 1999, 877:217-241.
10. Chieng B., Christie M.J. Somatostatin and nociceptin inhibit neurons in the central nucleus of amygdala that project to the periaqueductal grey. Neuropharmacology 2010, 59:425-430.
11. Chieng B.C., Christie M.J., Osborne P.B. Characterization of neurons in the rat central nucleus of the amygdala: cellular physiology, morphology, and opioid sensitivity. J. Comp. Neurol. 2006, 497:910-927.
12. Choi J.S., Kim J.J. Amygdala regulates risk of predation in rats foraging in a dynamic fear environment. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21773-21777.
13. Davis M., Walker D.L., Lee Y. Amygdala and bed nucleus of the stria terminalis: differential roles in fear and anxiety measured with the acoustic startle reflex. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1997, 352:1675-1687.
14. Davis M., Walker D.L., Lee Y. Roles of the amygdala and bed nucleus of the stria terminalis in fear and anxiety measured with the acoustic startle reflex. Possible relevance to PTSD. Ann. N. Y. Acad. Sci. 1997, 821:305-331.
15. Dielenberg R.A., Hunt G.E., McGregor I.S. "When a rat smells a cat": the distribution of Fos immunoreactivity in rat brain following exposure to a predatory odor. Neuroscience 2001, 104:1085-1097.
16. Drolet G., Dumont E.C., Gosselin I., Kinkead R., Laforest S., Trottier J.F. Role of endogenous opioid system in the regulation of the stress response. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:729-741.
17. Duncan G.E., Knapp D.J., Breese G.R. Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety. Brain Res. 1996, 713:79-91.
18. File S.E., Gonzalez L.E., Gallant R. Role of the basolateral nucleus of the amygdala in the formation of a phobia. Neuropsychopharmacology 1998, 19:397-405.
19. Gray T.S., Magnuson D.J. Peptide immunoreactive neurons in the amygdala and the bed nucleus of the stria terminalis project to the midbrain central gray in the rat. Peptides 1992, 13:451-460.
20. Handley S.L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch. Pharmacol. 1984, 327:1-5.
21. Haubensak W., Kunwar P.S., Cai H., Ciocchi S., Wall N.R., Ponnusamy R., Biag J., Dong H.W., Deisseroth K., Callaway E.M., Fanselow M.S., Luthi A., Anderson D.J. Genetic dissection of an amygdala microcircuit that gates conditioned fear. Nature 2010, 468:270-276.
22. Hebb A.L., Zacharko R.M., Gauthier M., Trudel F., Laforest S., Drolet G. Brief exposure to predator odor and resultant anxiety enhances mesocorticolimbic activity and enkephalin expression in CD-1 mice. Eur. J. Neurosci. 2004, 20:2415-2429.
23. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004, 38:213-224.
24. Herry C., Ciocchi S., Senn V., Demmou L., Muller C., Luthi A. Switching on and off fear by distinct neuronal circuits. Nature 2008, 454:600-606.
25. Herry C., Ferraguti F., Singewald N., Letzkus J.J., Ehrlich I., Luthi A. Neuronal circuits of fear extinction. Eur. J. Neurosci. 2010, 31:599-612.
26. Janitzky K., Stork O., Lux A., Yanagawa Y., Schwegler H., Linke R. Behavioral effects and pattern of brain c-fos mRNA induced by 2, 5-dihydro-2, 4, 5-trimethylthiazoline, a component of fox feces odor in GAD67-GFP knock-in C57BL/6 mice. Behav. Brain Res. 2009, 202:218-224.
27. Jovanovic T., Ressler K.J. How the neurocircuitry and genetics of fear inhibition may inform our understanding of PTSD. Am. J. Psychiatry 2010, 167:648-662.
28. Kask A., Harro J., von H.S., Redrobe J.P., Dumont Y., Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci. Biobehav. Rev. 2002, 26:259-283.
29. Koob G.F., Heinrichs S.C. A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. Brain Res. 1999, 848:141-152.
30. Koob G.F., Heinrichs S.C., Pich E.M., Menzaghi F., Baldwin H., Miczek K., Britton K.T. The role of corticotropin-releasing factor in behavioural responses to stress. Ciba Found. Symp. 1993, 172:277-289.
31. Linden A.M., Greene S.J., Bergeron M., Schoepp D.D. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions. Neuropsychopharmacology 2004, 29:502-513.
32. Martinez R.C., Carvalho-Netto E.F., Ribeiro-Barbosa E.R., Baldo M.V., Canteras N.S. Amygdalar roles during exposure to a live predator and to a predator-associated context. Neuroscience 2011, 172:314-328.
33. Masini C.V., Sasse S.K., Garcia R.J., Nyhuis T.J., Day H.E., Campeau S. Disruption of neuroendocrine stress responses to acute ferret odor by medial, but not central amygdala lesions in rats. Brain Res. 2009, 1288:79-87.
34. McDonald A.J. Somatostatinergic projections from the amygdala to the bed nucleus of the stria terminalis and medial preoptic-hypothalamic region. Neurosci. Lett. 1987, 75:271-277.
35. McDonald A.J. Coexistence of somatostatin with neuropeptide Y, but not with cholecystokinin or vasoactive intestinal peptide, in neurons of the rat amygdala. Brain Res. 1989, 500:37-45.
36. McDonald A.J., Betette R.L. Parvalbumin-containing neurons in the rat basolateral amygdala: morphology and co-localization of Calbindin-D(28k). Neuroscience 2001, 102:413-425.
37. McDonald A.J., Mascagni F. Immunohistochemical characterization of somatostatin containing interneurons in the rat basolateral amygdala. Brain Res. 2002, 943:237-244.
38. McDonald A.J., Pearson J.C. Coexistence of GABA and peptide immunoreactivity in non-pyramidal neurons of the basolateral amygdala. Neurosci. Lett. 1989, 100:53-58.
39. McDonald A.J., Shammah-Lagnado S.J., Shi C., Davis M. Cortical afferents to the extended amygdala. Ann. N. Y. Acad. Sci. 1999, 877:309-338.
40. McDonald A.J., Muller J.F., Mascagni F. GABAergic innervation of alpha type II calcium/calmodulin-dependent protein kinase immunoreactive pyramidal neurons in the rat basolateral amygdala. J. Comp. Neurol. 2002, 446:199-218.
41. Moga M.M., Gray T.S. Evidence for corticotropin-releasing factor, neurotensin, and somatostatin in the neural pathway from the central nucleus of the amygdala to the parabrachial nucleus. J. Comp. Neurol. 1985, 241:275-284.
42. Muller J.F., Mascagni F., McDonald A.J. Postsynaptic targets of somatostatin-containing interneurons in the rat basolateral amygdala. J. Comp. Neurol. 2007, 500:513-529.
43. Muller J.F., Mascagni F., McDonald A.J. Serotonin-immunoreactive axon terminals innervate pyramidal cells and interneurons in the rat basolateral amygdala. J. Comp. Neurol. 2007, 505:314-335.
44. Nestler E.J., Barrot M., Self D.W. DeltaFosB: a sustained molecular switch for addiction. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11042-11046.
45. Oberto A., Panzica G.C., Altruda F., Eva C. GABAergic and NPY-Y(1) network in the medial amygdala: a neuroanatomical basis for their functional interaction. Neuropharmacology 2001, 41:639-642.
46. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, New York.
47. Primeaux S.D., Wilson S.P., Cusick M.C., York D.A., Wilson M.A. Effects of altered amygdalar neuropeptide Y expression on anxiety-related behaviors. Neuropsychopharmacology 2005, 30:1589-1597.
48. Rodgers R.J., Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci. Biobehav. Rev. 1997, 21:801-810.
49. Rosen J.B., Donley M.P. Animal studies of amygdala function in fear and uncertainty: relevance to human research. Biol. Psychol. 2006, 73:49-60.
50. Sah P., Faber E.S., Lopez de A.M., Power J. The amygdaloid complex: anatomy and physiology. Physiol. Rev. 2003, 83:803-834.
51. Salome N., Salchner P., Viltart O., Sequeira H., Wigger A., Landgraf R., Singewald N. Neurobiological correlates of high (HAB) versus low anxiety-related behavior (LAB): differential Fos expression in HAB and LAB rats. Biol. Psychiatry 2004, 55:715-723.
52. Stock H.S., Hand G.A., Ford K., Wilson M.A. Changes in defensive behaviors following olfactory bulbectomy in male and female rats. Brain Res. 2001, 903:242-246.
53. Wilson M.A., Junor L. The role of amygdalar mu-opioid receptors in anxiety-related responses in two rat models. Neuropsychopharmacology 2008, 33:2957-2968.
54. Wray S., Hoffman G.E. Organization and interrelationship of neuropeptides in the central amygdaloid nucleus of the rat. Peptides 1983, 4:525-541.